Portfolio Tracker
Dein Depot in Echtzeit – Kurse, Renditeanalyse und Dividendenplaner an einem Ort.
Anzeige

BioVersys reports results from Phase 2a ENABLE study for tuberculosis treatments containing AlpE 20.11.2026, 07:00 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
BioVersys 22,50 CHF -5,86 % SIX Swiss (CHF)
Kostenlose Aktienchance per SMS Ausgewählte Trading-Einschätzungen aufs Handy.

BioVersys AG / Key word(s): Study results
BioVersys reports results from Phase 2a ENABLE study for tuberculosis treatments containing AlpE

20.11.2026 / 07:00 CET/CEST


Basel, Switzerland. November 20, 2026, 7.00am CET

  • Phase 2a ENABLE study showed early bactericidal activity in all regimens evaluated over 14 days in patients with newly diagnosed drug-sensitive pulmonary tuberculosis
  • AlpE combined with RZE achieved early bactericidal activity comparable to standard-of-care HRZE over 14 days
  • Findings support continued evaluation of AlpE-containing regimens

 

BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today results from the completed 14-day Phase 2a ENABLE study of alpibectir in combination with ethionamide (AlpE) in patients with newly diagnosed drug-sensitive pulmonary tuberculosis.

AlpE combines alpibectir with the anti-tuberculosis drug ethionamide and is being advanced through a collaboration between GSK and BioVersys for pulmonary TB and TB meningitis.

 

The phase 2a ENABLE study (NCT06748937) evaluated a 45 mg dose of alpibectir, higher than previously studied, in combination with 125mg or 250mg of ethionamide. AlpE was evaluated alone and in combination with rifampicin, pyrazinamide and ethambutol (RZE), replacing isoniazid in the standard-of-care HRZE regimen. The ENABLE study is conducted by TASK as part of the European Union Innovative Health Initiative Joint Undertaking (EU IHI JU) project UNITE4TB.

 

All regimens displayed bactericidal activity. Early bactericidal activity was ethionamide dose-dependent, with the regimen containing 250 mg ethionamide more active than the regimen containing 125 mg ethionamide. Although not designed for formal comparison between treatment arms, the AlpE 45 mg/250 mg-RZE regimen demonstrated EBA results that were numerically similar to standard-of-care HRZE, indicating that AlpE could potentially replace isoniazid in the treatment of isoniazid-resistant TB. AlpE was generally well tolerated and showed an acceptable safety profile over 14 days in this trial. 

 

Dr. David Barros-Aguirre, Head of Global Health Medicines R&D, GSK, and UNITE4TB Project Lead, said: “These early findings add to the growing clinical data for AlpE and support its continued evaluation as part of potential future TB regimens that could be simpler and more effective than those available today. By combining GSK’s science and innovation with the expertise of BioVersys and partners across UNITE4TB, we’re aiming to improve treatment options for people affected by TB.”

 

Dr. Marc Gitzinger, Chief Executive Officer, BioVersys, said: “The results from the Phase 2a ENABLE trial provide important clinical evidence supporting the continued development of AlpE as a potential component of future tuberculosis treatment regimens. Invaluable contributions from patients, investigators and partners made this study possible. We look forward to building on these results through the ongoing clinical programme and our continued collaboration with GSK. AlpE originated from a collaboration with Pasteur Institute Lille, BioVersys and GSK, and represents a formidable example of successful private-public partnerships to advance this important innovation into the space of global health. We are also grateful to the public funding agencies supporting this program such as EU IMI, EDCTP and others.”

 

Dr. Michel Pieren, Clinical Program Team Leader, BioVersys, said: "The clinical microbiology data presented at the Union Conference further strengthen our understanding of how alpibectir potentiates the activity of ethionamide and its active metabolite. These findings provide additional support for the mechanism underlying the clinical activity observed with AlpE and help inform the continued development of alpibectir-containing treatment regimens."

 

The results were presented at the Union World Conference on Lung Health, taking place from 17 to 20 November 2026 in Rio de Janeiro, Brazil. The conference programme included presentations covering the ENABLE efficacy, safety and pharmacokinetic findings, the further development of AlpE-containing regimens, and clinical data from an earlier Phase 2a study.

 

A separate clinical trial, STEP2C, conducted through UNITE4TB, with GSK and BioVersys supporting the clinical development of AlpE is currently evaluating the activity of AlpE-RZE during the first two months of treatment. This Phase 2b trial (NCT05807399) reported first-patient-first-visit in March 2026 and is conducted in six African countries under the European Union’s IMI2 UNITE4TB project, with the Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich as the trial sponsor. A separate Phase 2 programme is advancing in TB meningitis, led by BioVersys.

 


About BioVersys
BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. Derived from the company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company’s most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 3), and tuberculosis (alpibectir, Phase 2, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). BioVersys is located in the biotech hub of Basel, Switzerland.

About Alpibectir
Alpibectir (previously known as BVL-GSK098) is a small molecule developed from BioVersys’ award winning Transcriptional Regulatory Inhibitory Compounds (TRIC) platform in a successful collaboration with GSK, the Institut Pasteur Lille and the University of Lille. Alpibectir acts through a novel mode of action, potentiating the activity of the anti-TB drug ethionamide (Eto). Alpibectir is being studied for its potential to lower the efficacious human dose of Eto, minimizing of dose-dependent side effects, and overcome Eto resistance. The combination alpibectir/Eto (AlpE) is being developed for the treatment of pulmonary TB and TB meningitis. In 2023 AlpE was granted orphan-drug designation (ODD) for the treatment of tuberculosis, by the U.S. Food and Drug Administration (U.S. FDA) providing for certain incentives including seven years US market exclusivity. Similarly in 2025, AlpE was granted Orphan Designation from the European Medicines Agency (EMA), providing for certain incentives including 10-year EU market exclusivity.

About UNITE4TB
UNITE4TB is one of nine projects within the AMR Accelerator. Working across a global clinical trials network, UNITE4TB conducts regulatory standard Phase 2 clinical trials to accelerate clinical evaluation of novel drugs and combinations of drugs for tuberculosis (TB). Innovative adaptive trial designs, treatment response biomarkers, pharmacokinetic-pharmacodynamic models and Artificial Intelligence / Deep Learning techniques are integrated across study protocols, deploying cutting-edge methodologies to find antibiotic regimens with the highest likelihood of improved clinical efficacy.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101007873. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA, Deutsches Zentrum für Infektionsforschung e. V. (DZIF), and Ludwig-Maximilians-Universität München (LMU). EFPIA/AP contribute 50% of funding, whereas the contribution of DZIF and the LMU University Hospital Munich has been granted by the German Federal Ministry of Education and Research.

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning BioVersys and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioVersys to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioVersys is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

BioVersys contact 
Anca Cighi
, Head of IR and Communications, Tel. +41 79 949 33 09; Mail: anca.cighi@bioversys.com
For IR: IR@bioversys.com;  Website: www.bioversys.com



End of Media Release
View original content: EQS News


2438912  20.11.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Weitere News
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer